J&J joins Argenx, UCB in the myasthenia gravis arena with FDA approval for FcRn blocker Imaavy
The FDA on Wednesday approved J&J’s nipocalimab under the brand name Imaavy as a new treatment for generalized myasthenia gravis. The green light will likely tee off a showdown between J&J and established myasthenia gravis players Argenx and UCB.
The FDA on Wednesday approved J&J’s nipocalimab under the brand name Imaavy as a new treatment for generalized myasthenia gravis. The green light will likely tee off a showdown between J&J and established myasthenia gravis players Argenx and UCB.
